Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Provided By GlobeNewswire
Last update: Mar 25, 2024
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
